CCDC90B Inhibitors
CCDC90B inhibitors encompass a theoretical class of chemicals that could suppress the activity of CCDC90B by influencing specific signaling pathways or biological processes that are crucial for the protein's function. For example, the inhibition of mTOR signaling by compounds such as Rapamycin and Torin 1 can lead to the deactivation of downstream targets that may be essential for CCDC90B's activity. The action of these inhibitors would disrupt the necessary signaling for CCDC90B's function, which may rely on mTORC1-mediated phosphorylation events. The reduction of mTOR activity would result in a less favorable environment for CCDC90B activation or stability, leading to its functional inhibition.
Similarly, the PI3K/AKT pathway, which is pivotal for a multitude of cellular processes including growth, survival, and metabolism, can be blocked by inhibitors like Wortmannin and LY294002. These inhibitors prevent the activation of AKT, a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes. If CCDC90B is dependent on AKT signaling for its activity-perhaps requiring AKT-mediated phosphorylation for its stabilization or interaction with other proteins-then the inhibition of AKT would result in decreased CCDC90B activity. In addition, inhibitors such as PD98059 and U0126 target the MAPK/ERK pathway, which is involved in the regulation of gene expression, cellular growth, and survival. If CCDC90B is regulated by ERK signaling, perhaps by direct phosphorylation or through a cascade effect where ERK activates other proteins that in turn regulate CCDC90B, then these inhibitors would lead to reduced CCDC90B activity by blocking the MAPK/ERK pathway.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can reduce the activity of the mTORC1 complex. If CCDC90B function is reliant on mTORC1-mediated signaling for processes like protein synthesis or autophagy, the inhibition of this pathway by rapamycin would result in reduced CCDC90B activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor that impedes the PI3K/AKT/mTOR signaling pathway. By hindering PI3K, downstream effects on mTOR activity are observed, potentially diminishing CCDC90B activity if it is dependent on mTOR signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 also targets PI3K, blocking the PI3K/AKT pathway. This inhibition can decrease mTOR signaling, which may indirectly decrease CCDC90B activity if it is connected to the mTOR pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway. If CCDC90B is regulated by MAPK/ERK signaling, then PD98059 would lead to reduced CCDC90B activity by inhibiting this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibition of p38 MAPK can affect cellular stress responses, and if CCDC90B activity is modulated as part of this response, SB203580 would lead to diminished CCDC90B activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. If CCDC90B is activated by Src kinase signaling, dasatinib would reduce CCDC90B activity by blocking this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor which would inhibit the MAPK/ERK pathway. This would lead to decreased CCDC90B activity if CCDC90B is downstream of or regulated by this pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of misfolded proteins. If CCDC90B function requires proteasome activity for its turnover or for degradation of its regulatory proteins, bortezomib could indirectly inhibit CCDC90B function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is another proteasome inhibitor that can prevent the degradation of proteins involved in cellular regulation. If CCDC90B is regulated through proteasomal degradation, MG132 would lead to an indirect inhibition of its activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits AKT activation. If CCDC90B activity is AKT-dependent, the inhibition of AKT by triciribine would result in decreased CCDC90B activity. | ||||||